Matt Kalaycio, MD, a phenomenal leukemia specialist at the Cleveland Clinic, simplifies initial therapy and monitoring decisions for CML, financial implications for patients treated with TKIs, and treatment choices dictated by payers for patients with specific characteristics.
I recall the first presentation I have ever heard about Gleevec at a plenary session at ASH. Amazing how much we have advanced since and Matt summarizes everything for us.